Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAS2961
U.S. Govt. ID: NCT03709680
Contact: Luca Szalontay: 212-305-9770 / ls3399@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children with solid tumor which has come back or has not responded to the standard therapy. Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib will be given by mouth on Days 1-14 of a 21-day cycle. It will be given in combination with chemotherapy drugs Irinotecan and Temozolomide.
Investigator
Luca Szalontay, MD
Do You Qualify?
Does your child have a recurrent or refractory solid tumor? Yes No
Is your child between 2 and 21 years old? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Luca Szalontay
ls3399@cumc.columbia.edu
212-305-9770
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE